Novartis presented preliminary Phase 2 data evaluating Rhapsido, a drug recently approved for chronic spontaneous urticaria, in food allergy. The company reported that all three investigational doses produced higher response measures compared with control in the study, positioning Rhapsido as a potential repurposed therapy for food‑allergic patients. Novartis framed the readout as an early case to expand Rhapsido into a new indication; full safety and long‑term efficacy data were not included in the initial release. The company will need confirmatory trials powered for clinical endpoints to pursue label expansion. Allergy researchers and clinical development teams should monitor follow‑on randomized studies and regulatory discussions, since successful repurposing could shorten timelines but will require robust demonstration of benefit and safety in the food‑allergy population.